1
|
Ma G, Xu R, Pei W, Zhang Y, Ma R, Yang R, Zhao Z, Li Y, Feng C, Jin D, Ma W, Ma Y, Ma Z. Screening and validation of an alkaline-tolerant biomimetic affinity chromatography A5-87 resin for purification of discarded bovine serum Immunoglobulin G. J Chromatogr A 2024; 1714:464580. [PMID: 38154349 DOI: 10.1016/j.chroma.2023.464580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Revised: 12/09/2023] [Accepted: 12/13/2023] [Indexed: 12/30/2023]
Abstract
It is important to recycle the bovine blood discarded at slaughter and develop it into high value-added bovine serum products. Biomimetic affinity chromatography (BiAC) resins have been developed to specifically purify bovine serum immunoglobulin G (Bs-IgG). The BiAC strategy was used to screen the resins with the best purification effect on Bs-IgG. Four resins with specificity for Bs-IgG adsorption were selected from 90 BiAC resins. Finally, BiAC-A5-87 was selected and used to purify Bs-IgG based on the results of SDS-PAGE and BCA protein quantification analysis. The adsorption capacity and purity of BiAC-A5-87 were 32.79 ± 3.57 mg/mL and 85.9 ± 1.21 % for Bs-IgG, respectively. The total protein recovery rate of Bs-IgG purified by BiAC-A5-87 was 89.78±3.52 %. The resin of BiAC-A5-87 column was recycled in 40 breakthrough cycles, and its Bs-IgG adsorption efficiency decreased by less than 10 %. After soaking BiAC-A5-87 in 1.0 moL NaOH solution for 64 h, its adsorption capacity for Bs-IgG was almost the same as that before soaking. The development of waste bovine serum not only realizes the utilization of blood resources and produces high economic benefits but also reduces the pollution of the environment.
Collapse
Affiliation(s)
- Guorong Ma
- School of Basic Medicine, Ningxia Medical University, Yinchuan 750004, China.
| | - Ruiqiang Xu
- School of Basic Medicine, Ningxia Medical University, Yinchuan 750004, China
| | - Wang Pei
- School of Basic Medicine, Ningxia Medical University, Yinchuan 750004, China
| | - Yang Zhang
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China
| | - Rui Ma
- School of Basic Medicine, Ningxia Medical University, Yinchuan 750004, China
| | - Rang Yang
- School of Clinical Medicine, Ningxia Medical University, Yinchuan 750004, China
| | - Zhihao Zhao
- School of Clinical Medicine, Ningxia Medical University, Yinchuan 750004, China
| | - Yating Li
- School of Clinical Medicine, Ningxia Medical University, Yinchuan 750004, China
| | - Chenjie Feng
- College of Medical Information and Engineering, Ningxia Medical University, Yinchuan 750004, China
| | - Dongwu Jin
- Lanzhou Bailing Biotechnology Co. Ltd., Lanzhou 730010, China
| | - Wei Ma
- Lanzhou Bailing Biotechnology Co. Ltd., Lanzhou 730010, China
| | - Yumei Ma
- Lanzhou Bailing Biotechnology Co. Ltd., Lanzhou 730010, China
| | - Zhongren Ma
- Lanzhou Bailing Biotechnology Co. Ltd., Lanzhou 730010, China
| |
Collapse
|
2
|
Gehrmann N, Daxbacher A, Hahn R. Rapid purification of mAb using protein a membranes yielding high HCP clearance. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1232:123989. [PMID: 38154412 DOI: 10.1016/j.jchromb.2023.123989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/22/2023] [Accepted: 12/25/2023] [Indexed: 12/30/2023]
Abstract
Protein A chromatography remains the crucial step in mAb purification because of the high binding specificity and impurity clearance. In recent years, highly productive membrane adsorbers emerged as an alternative to traditional resins allowing for rapid purification of biomolecules. In this study, we tested three commercially available protein A membranes (Sartobind® Rapid A, HiTrap Fibro™ PrismA and GORE™ Protein Capture Device) regarding flow distribution, permeability and binding performance. As an application study using a cell-culture supernatant (CCS) containing monoclonal antibodies (mAbs), acidic and high pH wash steps were investigated regarding recovery and impurity removal. All membranes proved their applicability as highly productive capture media leading to high HCP and DNA removal with no observable influence on recovery. GORE™ Protein Capture Device exhibited a superior flow distribution but revealed diffusional limitations at high flow rates. Sartobind® Rapid A and HiTrap Fibro™ PrismA showed binding capacities of ∼ 40 g/L even at residence times (RTs) < 12 s but were limited by hydrodynamics suggesting room for improvement with optimized membrane housing.
Collapse
Affiliation(s)
- Nils Gehrmann
- Institute of Bioprocess Science and Engineering, Department of Biotechnology. University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
| | - Andreas Daxbacher
- Institute of Bioprocess Science and Engineering, Department of Biotechnology. University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
| | - Rainer Hahn
- Institute of Bioprocess Science and Engineering, Department of Biotechnology. University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria.
| |
Collapse
|
3
|
Huang H, Dong X, Sun Y, Shi Q. Biomimetic affinity chromatography for antibody purification: Host cell protein binding and impurity removal. J Chromatogr A 2023; 1707:464305. [PMID: 37607431 DOI: 10.1016/j.chroma.2023.464305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 08/04/2023] [Accepted: 08/16/2023] [Indexed: 08/24/2023]
Abstract
Peptide affinity chromatography has received increasing attention as an alternative to protein A chromatography in antibody purification. However, its lower selectivity than protein A chromatography has impeded its success in practical applications. In particular, efficient removal of contaminants, including host cell proteins (HCPs) and DNA, is a great challenge for peptide affinity chromatography in monoclonal antibody (mAb) manufacturing. In this work, a biomimetic peptide ligand (bPL), FYWHCLDE, was coupled onto Sepharose 6 Fast Flow (SepFF) to synthesize a peptide affinity gel, SepFF-bPL, for the investigation of the binding mechanism of HCP as well as the feasibility of antibody capture. The results showed that the SepFF-bPL column exhibited effective removal of mAb aggregates as well as mAb capture from feedstocks of various origins, whereas poor removal of HCP and DNA was found. Mechanistic studies of HCP binding indicated that electrostatic interactions dominated HCP binding on the SepFF-bPL gel and that ionic conductivity had a significant influence on HCP binding at low salt concentrations. Thus, combined chromatin extraction and anion exchange adsorption were introduced prior to SepFF-bPL chromatography for initial contaminant removal to reduce mAb aggregation induced by HCP and the loading burden of contaminants in SepFF-bPL chromatography. A proof-of-concept study of the purification train demonstrated a high recovery of mAb (68.7%) and low levels of HCP (23 ppm) and DNA (below the limit of detection) in the final product, which were acceptable for the mandatory requirements in clinical applications. This research provided a deep understanding of HCP binding on the peptide affinity column and led to the development of an effective purification train.
Collapse
Affiliation(s)
- Haotian Huang
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
| | - Xiaoyan Dong
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China; Key Laboratory of Systems Bioengineering and Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin 300350, China
| | - Yan Sun
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China; Key Laboratory of Systems Bioengineering and Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin 300350, China
| | - Qinghong Shi
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China; Key Laboratory of Systems Bioengineering and Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin 300350, China.
| |
Collapse
|
4
|
Doltade S, Saldanha M, Patil V, Dandekar P, Jain R. Statistically-aided development of protein A affinity chromatography for enhancing recovery and controlling quality of a monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1227:123829. [PMID: 37478555 DOI: 10.1016/j.jchromb.2023.123829] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 07/07/2023] [Accepted: 07/12/2023] [Indexed: 07/23/2023]
Abstract
Protein A chromatography is widely used for isolation of monoclonal antibodies (mAbs) from cell culture components. In this study, the effect of different process parameters of the Protein A purification namely, binding pH, elution pH, flow rate, neutralization pH and tween concentration, on the concentration and quality of the purified mAb were evaluated. Using design of experiments approach, the critical process parameters of protein A chromatography were identified and experimentally optimized. Their impact on quality attributes, such as size variants and charge variants, of the mAb was studied. Multivariate data analysis was subsequently performed using multiple linear regression and partial least squares regression methods. It was observed that the elution pH primarily governed the concentration of the purified mAb and the content of monomers and aggregates, while the tween concentration primarily influenced the main peak of the charge variants. This is the first study that evaluates the impact of tween concentration in buffers on the protein A chromatography purification step. These studies helped in identifying the design space and defining the target robust and optimal setpoints of the responses, which were subsequently verified experimentally. These setpoints not only passed the target criteria but also resulted in the highest recoveries during the investigation. Through this statistically-aided approach, an optimized and robust protein A chromatography process was rationally developed for purification of mAbs, while achieving the desired product quality. This study highlights the influence of multiple parameters of the protein A purification process on critical quality attributes of mAbs, such as the size and charge variants, which has been a very scarcely explored area.
Collapse
Affiliation(s)
- Shashikant Doltade
- Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Matunga, Mumbai 400019, India
| | - Marianne Saldanha
- Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Matunga, Mumbai 400019, India
| | - Vaibhav Patil
- Sartorius Stedim India Private Limited, No. 69/2 & 69/3, Jakkasandra, Nelamangala, Bangalore 562123, India
| | - Prajakta Dandekar
- Department of Pharmaceutical Science and Technology, Institute of Chemical Technology, Matunga, Mumbai 400019, India.
| | - Ratnesh Jain
- Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Matunga, Mumbai 400019, India.
| |
Collapse
|
5
|
Dhandapani G, Wachtel E, Patchornik G. Conjugated surfactant micelles: A non‐denaturing purification platform for concentrated human immunoglobulin G. NANO SELECT 2023. [DOI: 10.1002/nano.202200251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023] Open
|
6
|
Milne JJ. Scale-Up of Protein Purification: Downstream Processing Issues. Methods Mol Biol 2023; 2699:61-75. [PMID: 37646994 DOI: 10.1007/978-1-0716-3362-5_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Large-scale chromatography operations continue to occupy the central position in the overall strategy for downstream processing and purification of therapeutic protein products for human use. As the biopharmaceutical industry looks forward to embracing new therapeutic modalities such as viral vector-mediated gene therapy, it is becoming evident that chromatographic separations will be also be crucial for success in that discipline. The current industry focus on cell culture intensification strategies that can result in increased process efficiency and lower cost of goods is presenting challenges to the robustness and economics of chromatography processes. To ensure robust and reproducible commercial manufacturing strategies, there is always a mandate to increase the scale of chromatography unit operations that are typically developed and optimized in small-scale development trials. This chapter discusses the key factors in typical chromatography operations that need to be carefully considered and modeled during the process scale-up phase in order to maintain the purity, yield, and quality of a product purified at smaller scales.
Collapse
Affiliation(s)
- John Joseph Milne
- National Institute for Bioprocessing Research and Training (NIBRT), Blackrock, Dublin, Ireland.
| |
Collapse
|
7
|
Capela EV, Bairos J, Pedro AQ, Neves MC, Raquel Aires-Barros M, Azevedo AM, Coutinho JA, Tavares AP, Freire MG. Supported ionic liquids as customizable materials to purify immunoglobulin G. Sep Purif Technol 2023. [DOI: 10.1016/j.seppur.2022.122464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
8
|
Chu W, Prodromou R, Moore B, Elhanafi D, Kilgore R, Shastry S, Menegatti S. Development of Peptide Ligands for the Purification of α-1 Antitrypsin from Cell Culture Fluids. J Chromatogr A 2022; 1679:463363. [DOI: 10.1016/j.chroma.2022.463363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Revised: 07/19/2022] [Accepted: 07/20/2022] [Indexed: 11/16/2022]
|
9
|
Kurata H, Ishino T, Ohshima Y, Yohda M. CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem. Front Bioeng Biotechnol 2022; 10:841420. [PMID: 35387299 PMCID: PMC8978586 DOI: 10.3389/fbioe.2022.841420] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 03/07/2022] [Indexed: 12/14/2022] Open
Abstract
Biopharmaceutical industries have advanced significantly after the millennium. Novel biopharmaceuticals have been developed one after another, and blockbuster drugs have been produced. Accompanying the increase in the demand for biopharmaceuticals, a business model called “contract development manufacturing organization (CDMO)” has emerged. A CDMO is entrusted with the development and manufacturing of production processes from pharmaceutical companies. In this review, we identify the success factors of the biopharmaceutical CDMO by analyzing the foundry business for the semiconductor industry. Furthermore, we also review monoclonal antibody production platforms and new technologies that are critical aspects of differentiation strategies in the biopharmaceutical CDMO.
Collapse
Affiliation(s)
- Hideyuki Kurata
- Technology General Division, AGC Inc., Tokyo, Japan
- Institute of Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | - Tetsuya Ishino
- Technology General Division, AGC Inc., Tokyo, Japan
- AGC Biologics, Bothell, WA, United States
| | | | - Masafumi Yohda
- Institute of Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan
- *Correspondence: Masafumi Yohda,
| |
Collapse
|
10
|
Sánchez-Trasviña C, Flores-Gatica M, Enriquez-Ochoa D, Rito-Palomares M, Mayolo-Deloisa K. Purification of Modified Therapeutic Proteins Available on the Market: An Analysis of Chromatography-Based Strategies. Front Bioeng Biotechnol 2021; 9:717326. [PMID: 34490225 PMCID: PMC8417561 DOI: 10.3389/fbioe.2021.717326] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Accepted: 08/09/2021] [Indexed: 02/02/2023] Open
Abstract
Proteins, which have inherent biorecognition properties, have long been used as therapeutic agents for the treatment of a wide variety of clinical indications. Protein modification through covalent attachment to different moieties improves the therapeutic's pharmacokinetic properties, affinity, stability, confers protection against proteolytic degradation, and increases circulation half-life. Nowadays, several modified therapeutic proteins, including PEGylated, Fc-fused, lipidated, albumin-fused, and glycosylated proteins have obtained regulatory approval for commercialization. During its manufacturing, the purification steps of the therapeutic agent are decisive to ensure the quality, effectiveness, potency, and safety of the final product. Due to the robustness, selectivity, and high resolution of chromatographic methods, these are recognized as the gold standard in the downstream processing of therapeutic proteins. Moreover, depending on the modification strategy, the protein will suffer different physicochemical changes, which must be considered to define a purification approach. This review aims to deeply analyze the purification methods employed for modified therapeutic proteins that are currently available on the market, to understand why the selected strategies were successful. Emphasis is placed on chromatographic methods since they govern the purification processes within the pharmaceutical industry. Furthermore, to discuss how the modification type strongly influences the purification strategy, the purification processes of three different modified versions of coagulation factor IX are contrasted.
Collapse
Affiliation(s)
- Calef Sánchez-Trasviña
- Tecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Centro de Biotecnología-FEMSA, Monterrey, Mexico
| | - Miguel Flores-Gatica
- Tecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Centro de Biotecnología-FEMSA, Monterrey, Mexico
| | - Daniela Enriquez-Ochoa
- Tecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Centro de Biotecnología-FEMSA, Monterrey, Mexico
| | - Marco Rito-Palomares
- Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico
| | - Karla Mayolo-Deloisa
- Tecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Centro de Biotecnología-FEMSA, Monterrey, Mexico
| |
Collapse
|
11
|
Abstract
In the past 30 years, highly specific drugs, known as antibodies, have conquered the biopharmaceutical market. In addition to monoclonal antibodies (mAbs), antibody fragments are successfully applied. However, recombinant production faces challenges. Process analytical tools for monitoring and controlling production processes are scarce and time-intensive. In the downstream process (DSP), affinity ligands are established as the primary and most important step, while the application of other methods is challenging. The use of these affinity ligands as monitoring tools would enable a platform technology to monitor process steps in the USP and DSP. In this review, we highlight the current applications of affinity ligands (proteins A, G, and L) and discuss further applications as process analytical tools.
Collapse
|
12
|
|
13
|
Kip C, Hamaloğlu KÖ, Demir C, Tuncel A. Recent trends in sorbents for bioaffinity chromatography. J Sep Sci 2021; 44:1273-1291. [PMID: 33370505 DOI: 10.1002/jssc.202001117] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 12/22/2020] [Accepted: 12/23/2020] [Indexed: 12/24/2022]
Abstract
Isolation or enrichment of biological molecules from complex biological samples is mostly a prerequisite in proteomics, genomics, and glycomics. Different techniques have been used to advance the efficiency of the purification of biological molecules. Bioaffinity chromatography is one of the most powerful technique that plays an important role in the isolation of target biological molecules by the specific interactions with ligands that are immobilized on different support materials. This review examines the recent developments in bioaffinity chromatography particularly over the past 5 years in the literature. Also properties of supports, immobilization techniques, types of binding agents, and methods used in bioaffinity chromatography applications are summarized.
Collapse
Affiliation(s)
- Cigdem Kip
- Chemical Engineering Department, Hacettepe University, Ankara, Turkey
| | | | - Cihan Demir
- Chemical Engineering Department, Hacettepe University, Ankara, Turkey.,Nanotechnology and Nanomedicine Division, Hacettepe University, Ankara, Turkey
| | - Ali Tuncel
- Chemical Engineering Department, Hacettepe University, Ankara, Turkey
| |
Collapse
|
14
|
Park Y, Lee S, Kang H, Park M, Min K, Kim NH, Gu S, Kim JK, An DJ, Choe S, Sohn EJ. A classical swine fever virus E2 fusion protein produced in plants elicits a neutralizing humoral immune response in mice and pigs. Biotechnol Lett 2020; 42:1247-1261. [PMID: 32323080 PMCID: PMC7223222 DOI: 10.1007/s10529-020-02892-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 04/01/2020] [Accepted: 04/14/2020] [Indexed: 12/03/2022]
Abstract
Classical swine fever (CSF) is one of the most important viral diseases of swine worldwide. Although live or attenuated virus vaccines have been used to control CSFV, it is difficult to distinguish vaccinated pigs from infected pigs; this leads to restrictions on import and export. Subunit vaccines based on the CSFV E2 glycoprotein have been developed using baculovirus or insect cell systems, but some weaknesses remain. Here, we describe production of an E2 recombinant protein using a Nicotiana benthamiana plant expression system. To do this, we took advantage of the ability of the swine Fc domain to increase solubility and stability of the fusion protein and to strengthen immune responses in target animals. N. benthamiana expressed high amounts of pFc2-fused E2 proteins, which were isolated and purified by affinity chromatography to yield a high pure recombinant protein in a cost-effective manner. Native-polyacrylamide gel electrophoresis and size exclusion chromatography confirmed that the pmE2:pFc2 fusion exists as a multimer rather than as a dimer. Injection of recombinant pmE2 protein into mice or piglets generated anti-pmE2 antibodies with efficient neutralizing activity against CSFV. These results suggest that a purified recombinant E2 protein produced in N. benthamiana generates high titers of neutralizing antibodies in vivo; as such, the protein could be developed as a subunit vaccine against CSFV.
Collapse
Affiliation(s)
- Youngmin Park
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Sangmin Lee
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Hyangju Kang
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Minhee Park
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Kyungmin Min
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Nam Hyung Kim
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Sungmin Gu
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Jong Kook Kim
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea
| | - Dong-Jun An
- Virus Disease Division, Animal and Plant Quarantine Agency, Gimcheon, 39660, Gyeongbuk, Korea
| | - SeEun Choe
- Virus Disease Division, Animal and Plant Quarantine Agency, Gimcheon, 39660, Gyeongbuk, Korea
| | - Eun-Ju Sohn
- BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang, Korea.
| |
Collapse
|
15
|
Zhang J, Hu X, Dong X, Chen W, Zhang L, Chang Y, Wu Y, Wei W. Regulation of T Cell Activities in Rheumatoid Arthritis by the Novel Fusion Protein IgD-Fc-Ig. Front Immunol 2020; 11:755. [PMID: 32499775 PMCID: PMC7243948 DOI: 10.3389/fimmu.2020.00755] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Accepted: 04/03/2020] [Indexed: 12/21/2022] Open
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and T cell hyper-activation. Emerging evidence has shown that the stimulation of immunoglobulin D (IgD) induces T cell activation and may contribute to disease pathogenesis. In this study, the sIgD concentrations were positively associated with disease activity score in 28 joints (DAS28) and anti-cyclic citrullinated peptide (anti-CCP) in RA. We demonstrated that IgD-Fc-Ig (composed of human IgD Fc domain and IgG1 Fc domain, obtained through prokaryotic protein expression and chromatography purification) effectively inhibited the activation and proliferation of T cells in healthy controls and PBMCs in RA patients stimulated by IgD, recovered the Th17/Treg cell subset balance, and downregulated p-Lck and p-ZAP70 expression. Moreover, in vivo, IgD-Fc-Ig decreased the swollen joint counts and arthritis indices in mice with collagen-induced arthritis (CIA), and ameliorated histopathological changes in joint and spleen tissue. It also downregulated thymocyte proliferation and reduced the percentage of helper T cells (Th) and CD154+ T cells, reversed the imbalance of Th1/Th2 and Th17/Treg cell subsets, reduced cytokine and chemokine levels, and inhibited p-Lck and p-ZAP70 expression. Our data suggest that IgD-Fc-Ig fusion protein regulates T cell activity in RA. These findings have potential implications for IgD-targeted strategies to treat IgD-associated RA.
Collapse
Affiliation(s)
- Jing Zhang
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| | - Xiaoxi Hu
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| | - Xiaojie Dong
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| | - Wensheng Chen
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| | - Lingling Zhang
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| | - Yan Chang
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| | - Yujing Wu
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| | - Wei Wei
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China
| |
Collapse
|
16
|
Chahar DS, Ravindran S, Pisal S. Monoclonal antibody purification and its progression to commercial scale. Biologicals 2020; 63:1-13. [DOI: 10.1016/j.biologicals.2019.09.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 08/24/2019] [Accepted: 09/17/2019] [Indexed: 11/17/2022] Open
|
17
|
Li M, Zhang Q, Lin D, Yao S. Development and application of hydrophobic charge-induction chromatography for bioseparation. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1134-1135:121850. [DOI: 10.1016/j.jchromb.2019.121850] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 10/18/2019] [Accepted: 10/25/2019] [Indexed: 12/14/2022]
|
18
|
Chen G, Gerrior A, Durocher Y, Ghosh R. Efficient capture of monoclonal antibody from cell culture supernatant using protein A media contained in a cuboid packed-bed device. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1134-1135:121853. [DOI: 10.1016/j.jchromb.2019.121853] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 09/27/2019] [Accepted: 10/28/2019] [Indexed: 12/11/2022]
|
19
|
Pinto IF, Soares RRG, Aires‐Barros MR, Chu V, Conde JP, Azevedo AM. Optimizing the Performance of Chromatographic Separations Using Microfluidics: Multiplexed and Quantitative Screening of Ligands and Target Molecules. Biotechnol J 2019; 14:e1800593. [DOI: 10.1002/biot.201800593] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Revised: 05/20/2019] [Indexed: 02/06/2023]
Affiliation(s)
- Inês F. Pinto
- INESC Microsistemas e NanotecnologiasIN ‐ Institute of Nanoscience and Nanotechnology Rua Alves Redol 9 1000‐029 Lisbon Portugal
- IBB ‐ Institute for Bioengineering and Biosciences Instituto Superior TécnicoUniversidade de Lisboa Avenida Rovisco Pais 1 1049‐001 Lisbon Portugal
| | - Ruben R. G. Soares
- INESC Microsistemas e NanotecnologiasIN ‐ Institute of Nanoscience and Nanotechnology Rua Alves Redol 9 1000‐029 Lisbon Portugal
- IBB ‐ Institute for Bioengineering and Biosciences Instituto Superior TécnicoUniversidade de Lisboa Avenida Rovisco Pais 1 1049‐001 Lisbon Portugal
| | - Maria R. Aires‐Barros
- IBB ‐ Institute for Bioengineering and Biosciences Instituto Superior TécnicoUniversidade de Lisboa Avenida Rovisco Pais 1 1049‐001 Lisbon Portugal
- Department of Bioengineering Instituto Superior TécnicoUniversidade de Lisboa Avenida Rovisco Pais 1 1049‐001 Lisbon Portugal
| | - Virginia Chu
- INESC Microsistemas e NanotecnologiasIN ‐ Institute of Nanoscience and Nanotechnology Rua Alves Redol 9 1000‐029 Lisbon Portugal
| | - João P. Conde
- INESC Microsistemas e NanotecnologiasIN ‐ Institute of Nanoscience and Nanotechnology Rua Alves Redol 9 1000‐029 Lisbon Portugal
- Department of Bioengineering Instituto Superior TécnicoUniversidade de Lisboa Avenida Rovisco Pais 1 1049‐001 Lisbon Portugal
| | - Ana M. Azevedo
- IBB ‐ Institute for Bioengineering and Biosciences Instituto Superior TécnicoUniversidade de Lisboa Avenida Rovisco Pais 1 1049‐001 Lisbon Portugal
- Department of Bioengineering Instituto Superior TécnicoUniversidade de Lisboa Avenida Rovisco Pais 1 1049‐001 Lisbon Portugal
| |
Collapse
|
20
|
Innovative next-generation monoclonal antibody purification using activated carbon: A challenge for flow-through and column-free processes. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1121:72-81. [DOI: 10.1016/j.jchromb.2019.05.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 05/07/2019] [Accepted: 05/09/2019] [Indexed: 11/23/2022]
|
21
|
Brechmann NA, Eriksson PO, Eriksson K, Oscarsson S, Buijs J, Shokri A, Hjälm G, Chotteau V. Pilot-scale process for magnetic bead purification of antibodies directly from non-clarified CHO cell culture. Biotechnol Prog 2019; 35:e2775. [PMID: 30629859 PMCID: PMC6617771 DOI: 10.1002/btpr.2775] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 12/31/2018] [Accepted: 12/31/2018] [Indexed: 11/20/2022]
Abstract
High capacity magnetic protein A agarose beads, LOABeads PrtA, were used in the development of a new process for affinity purification of monoclonal antibodies (mAbs) from non‐clarified CHO cell broth using a pilot‐scale magnetic separator. The LOABeads had a maximum binding capacity of 65 mg/mL and an adsorption capacity of 25–42 mg IgG/mL bead in suspension for an IgG concentration of 1 to 8 g/L. Pilot‐scale separation was initially tested in a mAb capture step from 26 L clarified harvest. Small‐scale experiments showed that similar mAb adsorptions were obtained in cell broth containing 40 × 106 cells/mL as in clarified supernatant. Two pilot‐scale purification runs were then performed on non‐clarified cell broth from fed‐batch runs of 16 L, where a rapid mAb adsorption ≥96.6% was observed after 1 h. This process using 1 L of magnetic beads had an overall mAb yield of 86% and 16 times concentration factor. After this single protein A capture step, the mAb purity was similar to the one obtained by column chromatography, while the host cell protein content was very low, <10 ppm. Our results showed that this magnetic bead mAb purification process, using a dedicated pilot‐scale separation device, was a highly efficient single step, which directly connected the culture to the downstream process without cell clarification. Purification of mAb directly from non‐clarified cell broth without cell separation can provide significant savings in terms of resources, operation time, and equipment, compared to legacy procedure of cell separation followed by column chromatography step. © 2019 American Institute of Chemical Engineers Biotechnol. Prog., 35: e2775, 2019.
Collapse
Affiliation(s)
- Nils A Brechmann
- AdBIOPRO, VINNOVA Competence Centre for Advanced BioProduction by Continuous Processing, Stockholm, Sweden.,Cell Technology Group (CETEG), Dept. of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Inst. of Technology, Stockholm, Sweden
| | | | - Kristofer Eriksson
- AdBIOPRO, VINNOVA Competence Centre for Advanced BioProduction by Continuous Processing, Stockholm, Sweden.,Lab-on-a-Bead AB, Uppsala, Sweden
| | - Sven Oscarsson
- Dept. of Organic Chemistry, Stockholm University, Stockholm, Sweden
| | - Jos Buijs
- Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Atefeh Shokri
- AdBIOPRO, VINNOVA Competence Centre for Advanced BioProduction by Continuous Processing, Stockholm, Sweden.,Cell Technology Group (CETEG), Dept. of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Inst. of Technology, Stockholm, Sweden
| | - Göran Hjälm
- AdBIOPRO, VINNOVA Competence Centre for Advanced BioProduction by Continuous Processing, Stockholm, Sweden.,Lab-on-a-Bead AB, Uppsala, Sweden
| | - Véronique Chotteau
- AdBIOPRO, VINNOVA Competence Centre for Advanced BioProduction by Continuous Processing, Stockholm, Sweden.,Cell Technology Group (CETEG), Dept. of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Inst. of Technology, Stockholm, Sweden
| |
Collapse
|
22
|
Downstream Processing for Biopharmaceuticals Recovery. ENVIRONMENTAL CHEMISTRY FOR A SUSTAINABLE WORLD 2019. [DOI: 10.1007/978-3-030-01881-8_6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
23
|
Santarelli X, Cabanne C. Mixed Mode Chromatography: A Novel Way Toward New Selectivity. Curr Protein Pept Sci 2018; 20:14-21. [DOI: 10.2174/1389203718666171024121137] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 07/01/2017] [Accepted: 09/10/2017] [Indexed: 11/22/2022]
Abstract
Mixed mode chromatography offers a diversity of ligands, each providing a new selectivity.
This allows the design of novel purification processes with reduced column steps. Structure of ligands is
based on both hydrophobic and ionic groups. Thanks to its salt tolerance, crude extracts or post-IEX
samples can be loaded directly without conditioning. The selectivity could be enhanced by modulating
elution parameters or by using additives. More importantly, mixed mode chromatography could be as
effective as affinity chromatography for mAb purification processes. Mixed mode chromatography
opens the way to short and economical processes.
Collapse
|
24
|
Hirano A, Shiraki K, Kameda T. Effects of Arginine on Multimodal Chromatography: Experiments and Simulations. Curr Protein Pept Sci 2018; 20:40-48. [DOI: 10.2174/1389203718666171024115407] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 07/01/2017] [Accepted: 09/09/2017] [Indexed: 11/22/2022]
Abstract
Multimodal or mixed-mode chromatography can be used to separate various proteins, including
antibodies. The separation quality and efficiency have been improved by the addition of solutes, especially
arginine. This review summarizes the mechanism underlying the effects of arginine on protein
elution in multimodal chromatography with neutral, anionic or cationic resin ligands; the mechanism has
been investigated using experiments and molecular dynamics simulations. Arginine is effective in facilitating
protein elution compared to salts and protein denaturants such as guanidine and urea. The unique
elution effect of arginine can be explained by the interplay among arginine, proteins and the resin
ligands. Arginine exhibits multiple binding modes for the ligands and further affinity for protein aromatic
residues through its guanidinium group. These properties make arginine versatile for protein elution
in multimodal chromatography. Taking into account that arginine is an aggregation suppressor for
proteins but not a protein denaturant, arginine is a promising protein-eluting reagent for multimodal
chromatography.
Collapse
Affiliation(s)
- Atsushi Hirano
- Nanomaterials Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8565, Japan
| | - Kentaro Shiraki
- Institute of Applied Physics, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan
| | - Tomoshi Kameda
- Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Koto, Tokyo 135-0064, Japan
| |
Collapse
|
25
|
Rühl C, Knödler M, Opdensteinen P, Buyel JF. A linear epitope coupled to DsRed provides an affinity ligand for the capture of monoclonal antibodies. J Chromatogr A 2018; 1571:55-64. [PMID: 30104060 DOI: 10.1016/j.chroma.2018.08.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2018] [Revised: 07/19/2018] [Accepted: 08/05/2018] [Indexed: 12/16/2022]
Abstract
Monoclonal antibodies (mAbs) dominate the market for biopharmaceutical proteins because they provide active and passive immunotherapies for many different diseases. However, for most mAbs, two expensive manufacturing platforms are required. These are mammalian cell cultures for upstream production and Protein A chromatography for product capture during downstream processing. Here we describe a novel affinity ligand based on the fluorescent protein DsRed as a carrier for the linear epitope ELDKWA, which can capture the HIV-neutralizing antibody 2F5. We produced the DsRed-2F5-Epitope (DFE) in transgenic tobacco (Nicotiana tabacum) plants and purified it using a combination of heat treatment and immobilized metal-ion affinity chromatography, resulting in a yield of 24 mg kg-1 at 90% purity. Using a design-of-experiments approach, we coupled up to 15 mg DFE per mL Sepharose. The resulting affinity resin was able to capture 2F5 from the clarified extract of N. benthamiana plants, achieving a purity of 97%, a recovery of >95% and an initial dynamic binding capacity at 10% product breakthrough of 4 mg mL-1 after a contact time of 2 min. The resin capacity declined to 15% of the starting value within 25 cycles when 1.25 M magnesium chloride was used for elution. We confirmed the binding activity of the 2F5 product by surface plasmon resonance spectroscopy. DFE is not yet optimized, and a cost analysis revealed that boosting DFE expression and increasing its capacity by fourfold will make the resin cost-competitive with some Protein A counterparts. The affinity resin can also be exploited to purify idiotype-specific mAbs.
Collapse
Affiliation(s)
- C Rühl
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074 Aachen, Germany.
| | - M Knödler
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074 Aachen, Germany.
| | - P Opdensteinen
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074 Aachen, Germany.
| | - J F Buyel
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074 Aachen, Germany; Institute for Molecular Biotechnology, Worringerweg 1, RWTH Aachen University, 52074 Aachen, Germany.
| |
Collapse
|
26
|
Wang F, Yu T, Zheng H, Lao X. Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life. Sci Rep 2018; 8:12351. [PMID: 30120362 PMCID: PMC6097990 DOI: 10.1038/s41598-018-30956-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Accepted: 08/08/2018] [Indexed: 02/06/2023] Open
Abstract
Thymosin alpha 1 (Tα1) is a biological response modifier that has been introduced into markets for treating several diseases. Given the short serum half-life of Tα1 and the rapid development of Fc fusion proteins, we used genetic engineering method to construct the recombinant plasmid to express Tα1-Fc (Fc domain of human IgG4) fusion protein. A single-factor experiment was performed with different inducers of varying concentrations for different times to get the optimal condition of induced expression. Pure proteins higher than 90.3% were obtained by using 5 mM lactose for 4 h with a final production about 160.4 mg/L. The in vivo serum half-life of Tα1-Fc is 25 h, almost 13 times longer than Tα1 in mice models. Also, the long-acting protein has a stronger activity in repairing immune injury through increasing number of lymphocytes. Tα1-Fc displayed a more effective antitumor activity in the 4T1 and B16F10 tumor xenograft models by upregulating CD86 expression, secreting IFN-γ and IL-2, and increasing the number of tumor-infiltrating CD4+ T and CD8+ T cells. Our study on the novel modified Tα1 with the Fc segment provides valuable information for the development of new immunotherapy in cancer.
Collapse
Affiliation(s)
- Fanwen Wang
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, P.R. China
| | - Tingting Yu
- Dongyangguang pharmaceutical r&d co. LTD, Dongguan, 523000, P.R. China
| | - Heng Zheng
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, P.R. China.
| | - Xingzhen Lao
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, P.R. China.
| |
Collapse
|
27
|
Pabst TM, Thai J, Hunter AK. Evaluation of recent Protein A stationary phase innovations for capture of biotherapeutics. J Chromatogr A 2018; 1554:45-60. [DOI: 10.1016/j.chroma.2018.03.060] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 03/26/2018] [Accepted: 03/29/2018] [Indexed: 11/29/2022]
|
28
|
Hu X, Li G, Lin Y. A novel high-capacity immunoadsorbent with PAMAM dendritic spacer arms by click chemistry. NEW J CHEM 2018. [DOI: 10.1039/c8nj02142b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A novel immunoadsorbent with polyamidoamine dendritic spacer arms was prepared. Click chemistry can improve the reaction selectivity between the ligands and the support matrix under mild reaction conditions. The designed and prepared immunoadsorbent exhibits excellent adsorption for IgG. The IgG adsorption capacity of Sep-G3-His is superior to those of Sep-triazole-His and protein A immunoadsorbents.
Collapse
Affiliation(s)
- Xiaoyan Hu
- School of Materials Science and Engineering
- South China University of Technology
- Guangzhou
- China
| | - Guangji Li
- School of Materials Science and Engineering
- South China University of Technology
- Guangzhou
- China
| | - Yinlei Lin
- School of Materials Science and Energy Engineering
- Foshan University
- Foshan
- P. R. China
| |
Collapse
|
29
|
Arakawa T, Tokunaga M, Maruyama T, Shiraki K. Two Elution Mechanisms of MEP Chromatography. Curr Protein Pept Sci 2017; 20:28-33. [PMID: 29150920 DOI: 10.2174/1389203718666171117105132] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Revised: 11/02/2017] [Accepted: 11/08/2017] [Indexed: 11/22/2022]
Abstract
MEP (mercapto-ethyl-pyridine) HyperCel is one of the hydrophobic charge induction chromatography (HCIC) resins. Under normal operation, proteins are bound to the MEP resin at neutral pH, at which MEP is not charged, mostly via hydrophobic interaction. MEP has a pyridine group, whose pK is 4.8, and hence is positively charged at acidic pH range. Based on the binding mechanism (i.e., hydrophobic interaction) and the induced positive charge at acidic pH, there may be two ways to elute the bound proteins. One way is to bring the pH down to protonate both MEP resin and the bound protein, leading to charge repulsion and thereby elution. Another way is to use hydrophobic interaction modifiers, which are often used in hydrophobic interaction chromatography, to reduce hydrophobic interaction. Here, we summarize such two possible elution approaches.
Collapse
Affiliation(s)
- Tsutomu Arakawa
- Alliance Protein Laboratories, A Division of KBI Biopharma, 6042 Cornerstone Court West, San Diego, CA 92121, United States
| | - Masao Tokunaga
- Applied and Molecular Microbiology, Faculty of Agriculture, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan
| | - Takuya Maruyama
- Faculty of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305- 8573, Japan
| | - Kentaro Shiraki
- Faculty of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305- 8573, Japan
| |
Collapse
|
30
|
Gupta SK, Shukla P. Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review. Front Pharmacol 2017; 8:419. [PMID: 28725194 PMCID: PMC5495827 DOI: 10.3389/fphar.2017.00419] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Accepted: 06/13/2017] [Indexed: 11/27/2022] Open
Abstract
The protein productions strategies are crucial towards the development of application based research and elucidating the novel purification strategies for industrial production. Currently, there are few innovative avenues are studies for cloning, upstream, and purification through efficient bioprocess development. Such strategies are beneficial for industries as well as proven to be vital for effectual therapeutic protein development. Though, these techniques are well documented, but, there is scope of addition to current knowledge with novel and new approaches and it will pave new avenues in production of recombinant microbial and non-microbial proteins including secondary metabolites. In this review, we have focussed on the recent development in clone selection, various modern fermentation and purification technologies and future directions in these emerging areas. Moreover, we have also highlighted notable perspectives and challenges involved in the bioengineering of such proteins, including quality by design, gene editing and pioneering ideas. The biopharmaceutical industries continue to shift towards more flexible, automated platforms and economical product development, which in turn can help in developing the cost effective processes and affordable drug development for a large community.
Collapse
Affiliation(s)
- Sanjeev K Gupta
- Advanced Biotech Lab, Ipca Laboratories Ltd.,Mumbai, India.,Enzyme Technology and Protein Bioinformatics Laboratory, Department of Microbiology, Maharshi Dayanand UniversityRohtak, India
| | - Pratyoosh Shukla
- Enzyme Technology and Protein Bioinformatics Laboratory, Department of Microbiology, Maharshi Dayanand UniversityRohtak, India
| |
Collapse
|
31
|
Lu HL, Lin DQ, Zhang QL, Yao SJ. Evaluation on adsorption selectivity of immunoglobulin G with 2-mercapto-1-methyl-imidazole-based hydrophobic charge-induction resins. Biochem Eng J 2017. [DOI: 10.1016/j.bej.2016.12.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Abstract
Separation science continues to occupy the central position in the overall strategy for the downstream processing and purification of therapeutic protein products for human use. Increasing product titers from mammalian cell culture and new emerging classes of biopharmaceuticals has presented a challenge to the industry to identify ways of improving the robustness and economics of chromatography processes. In commercial manufacturing, there is always a need to increase the scale of the chromatography operations which are typically developed and optimized in small-scale laboratory experiments. This review discusses the key factors in the chromatography process that need to be considered as the scale of the purification step is increased in order to maintain the purity and integrity of the product purified at smaller scale.
Collapse
|
33
|
Luo YD, Zhang QL, Yuan XM, Shi W, Yao SJ, Lin DQ. Selectivity evaluation and separation of human immunoglobulin G, Fab and Fc fragments with mixed-mode resins. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1040:105-111. [DOI: 10.1016/j.jchromb.2016.11.036] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 11/06/2016] [Accepted: 11/26/2016] [Indexed: 11/30/2022]
|
34
|
Hirano A, Maruyama T, Shiraki K, Arakawa T, Kameda T. A study of the small-molecule system used to investigate the effect of arginine on antibody elution in hydrophobic charge-induction chromatography. Protein Expr Purif 2017; 129:44-52. [DOI: 10.1016/j.pep.2016.09.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 08/24/2016] [Accepted: 09/09/2016] [Indexed: 01/25/2023]
|
35
|
Arakawa T, Kurosawa Y, Storms M, Maruyama T, Okumura C, Kita Y. Capto MMC mixed-mode chromatography of murine and rabbit antibodies. Protein Expr Purif 2016; 127:105-110. [DOI: 10.1016/j.pep.2016.07.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 07/05/2016] [Accepted: 07/16/2016] [Indexed: 11/29/2022]
|
36
|
Zhang K, Liu X. Reprint of “Mixed-mode chromatography in pharmaceutical and biopharmaceutical applications”. J Pharm Biomed Anal 2016; 130:19-34. [DOI: 10.1016/j.jpba.2016.09.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Revised: 05/04/2016] [Accepted: 05/05/2016] [Indexed: 01/31/2023]
|
37
|
Evaluation of magnetic particles modified with a hydrophobic charge-induction ligand for antibody capture. J Chromatogr A 2016; 1460:61-7. [DOI: 10.1016/j.chroma.2016.07.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Revised: 06/30/2016] [Accepted: 07/03/2016] [Indexed: 11/21/2022]
|
38
|
Mixed-mode chromatography in pharmaceutical and biopharmaceutical applications. J Pharm Biomed Anal 2016; 128:73-88. [PMID: 27236100 DOI: 10.1016/j.jpba.2016.05.007] [Citation(s) in RCA: 114] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Revised: 05/04/2016] [Accepted: 05/05/2016] [Indexed: 01/19/2023]
Abstract
Mixed-mode chromatography (MMC) is a fast growing area in recent years, thanks to the new generation of mixed-mode stationary phases and better understanding of multimode interactions. MMC has superior applications in the separation of compounds that are not retained or not well resolved by typical reversed-phase LC methods, especially for polar and charged molecules. Due to the multiple retention modes that a single MMC column can offer, often MMC provides additional dimension to a separation method by adjusting the mobile phase conditions. Mixed-mode media is also an effective way to clean up complex sample matrices for purification purposes or for sensitive detection of trace amounts of analytes. In this article, we discuss mixed-mode stationary phases and separation mechanisms and review recent advances in pharmaceutical and biopharmaceutical applications including the analysis and/or purification of counterions, small molecule drugs, impurities, formulation excipients, peptides and proteins.
Collapse
|
39
|
Lin CP, Saito K, Boysen RI, Campi EM, Hearn MT. Static and dynamic binding behavior of an IgG2 monoclonal antibody with several new mixed mode affinity adsorbents. Sep Purif Technol 2016. [DOI: 10.1016/j.seppur.2016.02.048] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Müller E, Vajda J. Routes to improve binding capacities of affinity resins demonstrated for Protein A chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1021:159-168. [PMID: 26830536 DOI: 10.1016/j.jchromb.2016.01.036] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Revised: 12/19/2015] [Accepted: 01/19/2016] [Indexed: 12/13/2022]
Abstract
Protein A chromatography is a well-established platform in downstream purification of monoclonal antibodies. Dynamic binding capacities are continuously increasing with almost every newly launched Protein A resin. Nevertheless, binding capacities of affinity chromatography resins cannot compete with binding capacities obtained with modern ion exchange media. Capacities of affinity resins are roughly 50% lower. High binding capacities of ion exchange media are supported by spacer technologies. In this article, we review existing spacer technologies of affinity chromatography resins. A yet known effective approach to increase the dynamic binding capacity of Protein A resins is oligomerization of the particular Protein A motifs. This resembles the tentacle technology used in ion exchange chromatography. Dynamic binding capacities of a hexameric ligand are roughly twice as high compared to capacities obtained with a tetrameric ligand. Further capacity increases up to 130mg/ml can be realized with the hexamer ligand, if the sodium phosphate buffer concentration is increased from 20 to 100mM. Equilibrium isotherms revealed a BET shape for the hexamer ligand at monoclonal antibody liquid phase concentrations higher than 9mg/ml. The apparent multilayer formation may be due to hydrophobic forces. Other quality attributes such as recovery, aggregate content, and overall purity of the captured monoclonal antibody are not affected.
Collapse
Affiliation(s)
- Egbert Müller
- Tosoh Bioscience GmbH, Im Leuschnerpark 4, 64347 Griesheim, Germany.
| | - Judith Vajda
- Tosoh Bioscience GmbH, Im Leuschnerpark 4, 64347 Griesheim, Germany.
| |
Collapse
|
41
|
Tong HF, Lin DQ, Chu WN, Zhang QL, Gao D, Wang RZ, Yao SJ. Multimodal charge-induction chromatography for antibody purification. J Chromatogr A 2016; 1429:258-64. [DOI: 10.1016/j.chroma.2015.12.047] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Revised: 12/09/2015] [Accepted: 12/17/2015] [Indexed: 10/22/2022]
|
42
|
Ooi HW, Ketterer B, Trouillet V, Franzreb M, Barner-Kowollik C. Thermoresponsive Agarose Based Microparticles for Antibody Separation. Biomacromolecules 2015; 17:280-90. [DOI: 10.1021/acs.biomac.5b01391] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Huey Wen Ooi
- Preparative
Macromolecular Chemistry, Institut für Technische Chemie und
Polymerchemie, Karlsruhe Institute of Technology (KIT), Engesserstr. 18, 76128 Karlsruhe, Germany
| | | | | | | | - Christopher Barner-Kowollik
- Preparative
Macromolecular Chemistry, Institut für Technische Chemie und
Polymerchemie, Karlsruhe Institute of Technology (KIT), Engesserstr. 18, 76128 Karlsruhe, Germany
| |
Collapse
|
43
|
Brenac Brochier V, Ravault V. High throughput development of a non protein A monoclonal antibody purification process using mini-columns and bio-layer interferometry. Eng Life Sci 2015. [DOI: 10.1002/elsc.201400244] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
44
|
Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, Lencer WI, Pierce GF, Blumberg RS. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2015; 35:235-54. [PMID: 24156398 PMCID: PMC4876602 DOI: 10.3109/07388551.2013.834293] [Citation(s) in RCA: 181] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Nearly 350 IgG-based therapeutics are approved for clinical use or are under development for many diseases lacking adequate treatment options. These include molecularly engineered biologicals comprising the IgG Fc-domain fused to various effector molecules (so-called Fc-fusion proteins) that confer the advantages of IgG, including binding to the neonatal Fc receptor (FcRn) to facilitate in vivo stability, and the therapeutic benefit of the specific effector functions. Advances in IgG structure-function relationships and an understanding of FcRn biology have provided therapeutic opportunities for previously unapproachable diseases. This article discusses approved Fc-fusion therapeutics, novel Fc-fusion proteins and FcRn-dependent delivery approaches in development, and how engineering of the FcRn-Fc interaction can generate longer-lasting and more effective therapeutics.
Collapse
Affiliation(s)
- Timo Rath
- Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Kristi Baker
- Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | | | | | - Shuo-Wang Qiao
- Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
| | - Wayne I. Lencer
- Division of Gastroenterology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Richard S. Blumberg
- Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
45
|
Purification process of recombinant monoclonal antibodies with mixed mode chromatography. J Chromatogr A 2015; 1393:57-64. [DOI: 10.1016/j.chroma.2015.03.018] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 03/06/2015] [Accepted: 03/07/2015] [Indexed: 11/21/2022]
|
46
|
Liu T, Lin DQ, Zhang QL, Yao SJ. Characterization of immunoglobulin adsorption on dextran-grafted hydrophobic charge-induction resins: Cross-effects of ligand density and pH/salt concentration. J Chromatogr A 2015; 1396:45-53. [DOI: 10.1016/j.chroma.2015.03.074] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 03/14/2015] [Accepted: 03/25/2015] [Indexed: 12/01/2022]
|
47
|
Yu G, Liu J, Zhou J. Mesoscopic coarse-grained simulations of hydrophobic charge induction chromatography (HCIC) for protein purification. AIChE J 2015. [DOI: 10.1002/aic.14805] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Gaobo Yu
- School of Chemistry and Chemical Engineering, Guangdong Provincial Key Lab for Green Chemical Product Technology, South China University of Technology; Guangzhou 510640 P.R. China
| | - Jie Liu
- School of Chemistry and Chemical Engineering, Guangdong Provincial Key Lab for Green Chemical Product Technology, South China University of Technology; Guangzhou 510640 P.R. China
| | - Jian Zhou
- School of Chemistry and Chemical Engineering, Guangdong Provincial Key Lab for Green Chemical Product Technology, South China University of Technology; Guangzhou 510640 P.R. China
| |
Collapse
|
48
|
|
49
|
Cheng F, Li MY, Wang HQ, Lin DQ, Qu JP. Antibody-ligand interactions for hydrophobic charge-induction chromatography: a surface plasmon resonance study. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2015; 31:3422-3430. [PMID: 25734470 DOI: 10.1021/la5044987] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
This article describes the use of surface plasmon resonance (SPR) spectroscopy to study antibody-ligand interactions for hydrophobic charge-induction chromatography (HCIC) and its versatility in investigating the surface and solution factors affecting the interactions. Two density model surfaces presenting the HCIC ligand (mercapto-ethyl-pyridine, MEP) were prepared on Au using a self-assembly technique. The surface chemistry and structure, ionization, and protein binding of such model surfaces were characterized by X-ray photoelectron spectroscopy (XPS), near-edge X-ray absorption fine structure (NEXAFS), contact-angle titration, and SPR, respectively. The influences of the surface and solution factors, e.g., ligand density, salt concentration, and solution pH, on protein adsorption were determined by SPR. Our results showed that ligand density affects both equilibrium and dynamic aspects of the interactions. Specifically, a dense ligand leads to an increase in binding strength, rapid adsorption, slow desorption, and low specificity. In addition, both hydrophobic interactions and hydrogen bonding contribute significantly to the protein adsorption at neutral pH, while the electrostatic repulsion is overwhelmed under acidic conditions. The hydrophobic interaction at a high concentration of lyotropic salt would cause drastic conformational changes in the adsorbed protein. Combined with the self-assembly technique, SPR proves to be a powerful tool for studying the interactions between an antibody and a chromatographic ligand.
Collapse
Affiliation(s)
| | - Ming-Yang Li
- §School of Life Science and Biotechnology, Dalian University of Technology, Dalian 116023, China
| | | | - Dong-Qiang Lin
- ∥Department of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China
| | | |
Collapse
|
50
|
Herzer S, Bhangale A, Barker G, Chowdhary I, Conover M, O'Mara BW, Tsang L, Wang SY, Krystek SR, Yao Y, Rieble S. Development and scale-up of the recovery and purification of a domain antibody Fc fusion protein-comparison of a two and three-step approach. Biotechnol Bioeng 2015; 112:1417-28. [DOI: 10.1002/bit.25561] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 02/06/2015] [Indexed: 01/22/2023]
Affiliation(s)
- Sibylle Herzer
- Biologics Development; BLY-106G, Bristol-Myers Squibb; 519 Route 173 West, Bloomsbury New Jersey
| | | | | | | | - Matthew Conover
- Biologics Development; BLY-106G, Bristol-Myers Squibb; 519 Route 173 West, Bloomsbury New Jersey
| | | | - Lily Tsang
- Biologics Development; BMS; Seattle Washington
| | | | | | - Yan Yao
- Biologics Development; BMS; Bloomsbury New Jersey
| | | |
Collapse
|